Metabolic Surgery for Atrial Fibrillation Elimination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-01

Study Completion Date

2030-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation.

The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery

NCT05543278

Surgery, Cardiac Atrial Fibrillation

NOT_YET_RECRUITING PHASE4

Management of New-Onset Postoperative Atrial Fibrillation

NCT01395836

Atrial Fibrillation Coronary Artery Disease Post Operative Arrythmia

COMPLETED

A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery

NCT05780320

Atrial Fibrillation New Onset

COMPLETED

Evaluation of the Cardioblate CryoFlex Surgical Ablation System in Longstanding Persistent Atrial Fibrillation

NCT01558635

Longstanding Persistent Atrial Fibrillation

TERMINATED NA

Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery

NCT00127712

Atrial Fibrillation

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is randomized trial of 100 patients with BMI ≥35 kg/m2 and AF. Patients who met the initial screening criteria (including presence of at least 1% AF burden during a 2-week monitoring period with an ambulatory cardiac monitor) will be invited for possible enrollment. Patients will then be randomized 1:1 to MBS group versus nonsurgical control group and will be followed for 12 months (phase 1) and then for an additional 18 months (phase 2).

Interventions include Roux-en-Y Gastric Bypass or Sleeve Gastrectomy surgical procedures based on the shared medical decision between the bariatric surgeon and patients considering the patient's conditions. In the control group, patients are allowed to take anti-obesity medications (AOMs) that are not contraindicated in patients with AF at the discretion of obesity medicine specialists.

Lifestyle and risk factor modification in both groups will consist of targeted and personalized diet plans, exercise, and risk factor reduction, including optimal therapies for T2DM, hypertension, dyslipidemia, heart failure, coronary artery disease, and OSA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Obesity and Obesity-related Medical Conditions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

METSAFE is a randomized open-label blinded-endpoint single-center controlled efficacy/safety study with 2 parallel groups of patients with obesity and AF who will either receive metabolic surgery or nonsurgical obesity care for 30 months. The study has 2 phases: the first 12 months and the subsequent 18 months.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Patients and investigators will not be blinded to treatment assignment. However, the clinical assessors of cardiac rhythm recorders are blinded to the study arms; Assessment of the primary endpoint will be based on the blinded downloads and interpretation of Zio XT Patch (iRhythm) data yielding the AF burden.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metabolic Surgery

Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG)

Group Type ACTIVE_COMPARATOR

Roux-en-Y Gastric Bypass or Sleeve Gastrectomy

Intervention Type PROCEDURE

Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure.

Control group (nonsurgical standard of care for obesity)

In the Control group, the subjects will be receiving standard of care for nonsurgical management of obesity, including possible AOMs that are not contraindicated in patients with AF at the discretion of obesity medicine specialists.

Group Type OTHER

Anti-Obesity Medication (AOM) treatment

Intervention Type DRUG

Implementation of obesity pharmacotherapy in the nonsurgical group includes initial assessment of side effects and response, followed by achieving a clinically meaningful weight loss (5% weight loss) after three months. Once this goal is reached, AOMs will be continued throughout the study. If a weight plateau is reached within the first AOM, then another AOM may be added in combination in a stepwise fashion. The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Roux-en-Y Gastric Bypass or Sleeve Gastrectomy

Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure.

Intervention Type PROCEDURE

Anti-Obesity Medication (AOM) treatment

Implementation of obesity pharmacotherapy in the nonsurgical group includes initial assessment of side effects and response, followed by achieving a clinically meaningful weight loss (5% weight loss) after three months. Once this goal is reached, AOMs will be continued throughout the study. If a weight plateau is reached within the first AOM, then another AOM may be added in combination in a stepwise fashion. The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Roux-en-Y Gastric Bypass (RYGB) Sleeve Gastrectomy (SG) Bariatric Surgery

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Entry into the study would require that the patient:

1. Is a candidate for general anesthesia
2. Is eligible for metabolic surgery (RYGB or SG)
3. Is ≥18 and ≤80 years old
4. has a BMI ≥35 and ≤65 kg/m2
5. has AF criteria, which:

1. Must be documented by EKG or cardiac monitor or Zio XT Patch
2. Must have symptomatic AF
3. In terms of types of AF, either paroxysmal AF with at least one episode lasting ≥5 minutes in the last 3 months prior to screening, or persistent AF, or longstanding AF.
4. Must have a minimum burden of 1% during a 2-week screening time with an ambulatory noninvasive cardiac monitor.
5. Must be assessed and confirmed by an expert cardiologist (e.g., cardiac electrophysiologist) to meet eligibility.
6. Patients without history of prior AF ablation/PVI procedure or with history of prior failed AF ablation/PVI procedure are eligible for the study.
7. Patients with and without T2DM are eligible for the study. Patients with T2DM should have been on a stable dose of anti-diabetic medication (including insulin) for at least 3 months prior to entry, with HbA1c ≤12%.
8. Have the ability and willingness to participate in the study and agree to any of the arms involved in the study.
9. Able to understand the options and to comply with the requirements of each arm.
10. Have a negative urine pregnancy test at screening and randomization visits for women of childbearing potential.
11. Women, of childbearing age, must agree to use reliable method of contraception for 2 years.

Exclusion Criteria

1. Significant cardiac valvular disease (planned to undergo cardiac valve intervention/surgery in the next 12 months)
2. Significant atherosclerotic disease (planned to undergo coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)
3. Severe uncompensated cardiopulmonary disease leading to American Society of Anesthesiologists Class IV or V
4. Classified as New York Heart Association Class IV
5. Left ventricular ejection fraction \<20% at the time of screening
6. Hospitalization for myocardial infarction, unstable angina, stroke, transient ischemic attack, heart surgery, coronary stent placement in the past 6 months
7. Prior bariatric and metabolic surgery of any kind (patients who had a gastric balloon or gastric band that were removed more than one year prior to enrollment are allowed to participate)
8. History of solid organ transplant
9. Type 1 diabetes or autoimmune diabetes
10. eGFR \< 30 mL/min/1.73 m2 at screening or being on dialysis
11. Decompensated cirrhosis characterized by ascites, hepatic encephalopathy, portal hypertension, or esophageal varices.
12. Anemia defined as hemoglobin less than 9 g/dL
13. Use of investigational therapy
14. Liver transaminase level \>300 U/L
15. Significant alcohol use (average \>2 drinks/day)
16. Presence of active malignancy (except non-melanoma skin cancer)
17. Life expectancy less than 3 years due to concomitant diseases
18. Major mental health, psychological disorders, or substance abuse disorders that in the opinion of the investigators could disqualify the patient from metabolic surgery
19. Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study
20. Unable to understand the risks, benefits and compliance requirements of study
21. Lack capacity to give informed consent
22. Plans to move outside the primary location of study (Northeast Ohio) within the next 12 months
23. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures
24. Known adhesive allergies

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes